MA49414A - Protéines de fusion de dmdv et e2 et leurs utilisations - Google Patents

Protéines de fusion de dmdv et e2 et leurs utilisations

Info

Publication number
MA49414A
MA49414A MA049414A MA49414A MA49414A MA 49414 A MA49414 A MA 49414A MA 049414 A MA049414 A MA 049414A MA 49414 A MA49414 A MA 49414A MA 49414 A MA49414 A MA 49414A
Authority
MA
Morocco
Prior art keywords
dmdv
fusion proteins
fusion
proteins
Prior art date
Application number
MA049414A
Other languages
English (en)
Inventor
Jean-Christophe Audonnet
Natalia Bomchil
Frederic Reynard
Cecile Sigoillot-Claude
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Publication of MA49414A publication Critical patent/MA49414A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/135Foot- and mouth-disease virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA049414A 2015-11-23 2016-11-16 Protéines de fusion de dmdv et e2 et leurs utilisations MA49414A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562259043P 2015-11-23 2015-11-23

Publications (1)

Publication Number Publication Date
MA49414A true MA49414A (fr) 2020-04-22

Family

ID=57570585

Family Applications (3)

Application Number Title Priority Date Filing Date
MA043310A MA43310A (fr) 2015-11-23 2016-11-16 Protéines de fusion de fmdv et e2 et leurs utilisations
MA42640A MA42640B1 (fr) 2015-11-23 2016-11-16 Protéines de fusion de dmdv et e2 et leurs utilisations
MA049414A MA49414A (fr) 2015-11-23 2016-11-16 Protéines de fusion de dmdv et e2 et leurs utilisations

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA043310A MA43310A (fr) 2015-11-23 2016-11-16 Protéines de fusion de fmdv et e2 et leurs utilisations
MA42640A MA42640B1 (fr) 2015-11-23 2016-11-16 Protéines de fusion de dmdv et e2 et leurs utilisations

Country Status (20)

Country Link
US (2) US9913891B2 (fr)
EP (2) EP3539566A1 (fr)
JP (2) JP6797206B2 (fr)
KR (1) KR102153303B1 (fr)
CN (1) CN108367067B (fr)
AR (1) AR106792A1 (fr)
AU (1) AU2016361305B2 (fr)
BR (1) BR112018010494A8 (fr)
CA (1) CA3006078A1 (fr)
DK (1) DK3380119T3 (fr)
ES (1) ES2899230T3 (fr)
HK (1) HK1258695A1 (fr)
MA (3) MA43310A (fr)
MX (1) MX2018006347A (fr)
NZ (1) NZ743236A (fr)
RU (1) RU2714428C2 (fr)
TW (1) TWI744260B (fr)
UY (1) UY36995A (fr)
WO (1) WO2017091418A1 (fr)
ZA (1) ZA201803390B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019179345A1 (fr) * 2018-03-19 2019-09-26 Boehringer Ingelheim (China) Investment Co., Ltd. Virus recombinant capable d'exprimer de manière stable des protéines cibles
CN109187993B (zh) * 2018-09-13 2020-06-16 中国农业科学院兰州兽医研究所 一种口蹄疫A型病毒sIgA抗体ELISA检测试剂盒及其应用
CN111233984B (zh) * 2018-11-29 2022-08-12 普莱柯生物工程股份有限公司 一种o型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用
CN110028160B (zh) * 2019-01-24 2022-04-29 暨南大学 一种功能性微藻固定化材料的制备方法及其应用
KR102672787B1 (ko) * 2019-06-28 2024-06-05 (주)플럼라인생명과학 구제역 바이러스 백신 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP0173552B1 (fr) 1984-08-24 1991-10-09 The Upjohn Company Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IE872455L (en) 1986-09-12 1988-03-12 Lanstrase Ltd Improved recombinant expression
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
EP0575491B1 (fr) 1991-03-07 2003-08-13 Virogenetics Corporation Souche de vaccin mise au point par genie genetique
EP0826063A1 (fr) 1995-04-25 1998-03-04 Vical Incorporated Formulations en ampoule unidose de complexes adn/lipides
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
EP1537877A3 (fr) 1996-10-11 2005-08-03 The Regents Of The University Of California Conjugués polynucléotides immunostimulateurs/molécule immunomodulatrice
BR9810369A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
GB9929151D0 (en) * 1999-12-09 2000-02-02 Univ Cambridge Tech Peptide and polypeptide display
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7371395B2 (en) 2003-07-24 2008-05-13 Merial Limited Vaccine formulations
WO2006073431A2 (fr) 2004-06-25 2006-07-13 Merial Limited Genes du virus de la fievre aphteuse exprimant des recombines avipox
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
EP2316480A1 (fr) * 2006-03-17 2011-05-04 Indian Immunologicals Ltd Particles de type Tymovirus chimériques
CN101293098A (zh) * 2007-04-28 2008-10-29 北京迪威华宇生物技术有限公司 一种重组牛o型口蹄疫病毒融合蛋白疫苗
PL2475384T3 (pl) 2009-09-10 2017-02-28 Merial, Inc. Nowe formulacje szczepionek obejmujące adiuwanty zawierające saponiny
CA2792117C (fr) 2010-03-12 2016-09-20 Merial Limited Vaccins de recombinaison contre le virus de la fievre aphteuse et utilisations de ceux-ci
RU2467014C2 (ru) * 2010-12-06 2012-11-20 Учреждение Российской академии наук Центр "Боинженерия" РАН Полиэпитопный белок, нуклеотидная последовательность, кодирующая полиэпитопный белок, плазмида с последовательностью, кодирующей полиэпитопный белок, и препарат полиэпитопного белка для индукции иммунного ответа против вируса ящура
KR20150084993A (ko) * 2012-11-16 2015-07-22 유나이티드 바이오메디칼 인크. 구제역 (fmd)에 대한 합성 펩티드-기재 응급 백신
BR112015013135A2 (pt) * 2012-12-05 2017-09-26 Thevax Genetics Vaccine Co Ltd proteínas de fusão para uso como potencializadores imunogênicos para induzir respostas de células t antígeno específicas
CN103305542B (zh) * 2013-06-25 2015-03-11 江苏省农业科学院 一种重组噬菌体双表达载体及应用
EP3906939A1 (fr) * 2013-10-11 2021-11-10 The United States of America, represented by the Secretary, Department of Health and Human Services Vaccins contre le virus d'epstein-barr
CN103933581A (zh) * 2014-05-04 2014-07-23 贵州大学 一种基于csf-fmd二联基因工程疫苗的制备方法
CN107073100B (zh) 2014-09-23 2021-02-26 勃林格殷格翰动物保健美国公司 Fmdv重组疫苗及其用途

Also Published As

Publication number Publication date
JP2020203890A (ja) 2020-12-24
RU2018122755A (ru) 2019-12-26
KR20180084995A (ko) 2018-07-25
AU2016361305B2 (en) 2020-02-06
US20180169216A1 (en) 2018-06-21
MA42640A1 (fr) 2019-05-31
EP3539566A1 (fr) 2019-09-18
BR112018010494A2 (pt) 2018-11-13
DK3380119T3 (da) 2021-11-15
UY36995A (es) 2017-06-30
CA3006078A1 (fr) 2017-06-01
NZ743236A (en) 2019-12-20
CN108367067B (zh) 2022-05-03
BR112018010494A8 (pt) 2019-02-26
TWI744260B (zh) 2021-11-01
MX2018006347A (es) 2019-02-20
US10363300B2 (en) 2019-07-30
AR106792A1 (es) 2018-02-21
ZA201803390B (en) 2019-03-27
WO2017091418A1 (fr) 2017-06-01
RU2714428C2 (ru) 2020-02-14
US20170143819A1 (en) 2017-05-25
EP3380119A1 (fr) 2018-10-03
MA43310A (fr) 2021-04-28
JP6797206B2 (ja) 2020-12-09
RU2018122755A3 (fr) 2019-12-26
HK1258695A1 (zh) 2019-11-15
EP3380119B1 (fr) 2021-08-25
US9913891B2 (en) 2018-03-13
AU2016361305A1 (en) 2018-06-28
TW201726708A (zh) 2017-08-01
MA42640B1 (fr) 2021-06-30
KR102153303B1 (ko) 2020-09-09
JP2019500409A (ja) 2019-01-10
CN108367067A (zh) 2018-08-03
ES2899230T3 (es) 2022-03-10

Similar Documents

Publication Publication Date Title
MA44986A (fr) Protéines de fusion gdf15 et leurs utilisations
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
DK3292141T3 (da) Fusionsproteiner
MA50618A (fr) Polyrhérapies et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
MA53883A (fr) Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
KR20180084895A (ko) 효소 내재화 조성물 및 방법
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA43529A (fr) Modulateurs de transport nucléaire et leurs utilisations
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
MA41919A (fr) Hétéromultimères alk4:actriib et leurs utilisations
DK3107562T3 (da) P97-ids-fusionsproteiner
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA53991A (fr) Protéines de fusion de l'inhibiteur de la c1 estérase et leurs utilisations
MA44489A (fr) Pyrimidines et variants de celles-ci, et leurs utilisations